{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:32:19Z","timestamp":1780047139770,"version":"3.53.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Endocrinology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.mce.2019.01.013","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T07:37:56Z","timestamp":1547624276000},"page":"54-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Relaxin-2 for heart failure with preserved ejection fraction (HFpEF): Rationale for future clinical trials"],"prefix":"10.1016","volume":"487","author":[{"given":"Thomas Bernd","family":"Dschietzig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mce.2019.01.013_bib1","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/CIRCHEARTFAILURE.113.001229","article-title":"Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction","volume":"7","author":"Adamson","year":"2014","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.mce.2019.01.013_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075592","article-title":"Relaxin protects rat lungs from ischemia-reperfusion injury via inducible NO synthase: role of ERK-1\/2, PI3K, and forkhead transcription factor FKHRL1","volume":"8","author":"Alexiou","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.mce.2019.01.013_bib3","doi-asserted-by":"crossref","first-page":"R662","DOI":"10.1152\/ajpregu.00214.2007","article-title":"Reversal by relaxin of altered ileal spontaneous contractions in dystrophic (mdx) mice through a nitric oxide-mediated mechanism","volume":"293","author":"Baccari","year":"2007","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.mce.2019.01.013_bib4","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1161\/01.HYP.31.6.1240","article-title":"Relaxin activates the L-arginine-nitric oxide pathway in vascular smooth muscle cells in culture","volume":"31","author":"Bani","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.mce.2019.01.013_bib5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1152\/physrev.00001.2012","article-title":"Relaxin family peptides and their receptors","volume":"93","author":"Bathgate","year":"2013","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.mce.2019.01.013_bib6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.bbrc.2017.06.091","article-title":"Relaxin reduces susceptibility to post-infarct atrial fibrillation in mice due to anti-fibrotic and anti-inflammatory properties","volume":"490","author":"Beiert","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.mce.2019.01.013_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijcard.2017.09.017","article-title":"Chronic lower-dose relaxin administration protects from arrhythmia in experimental myocardial infarction due to anti-inflammatory and anti-fibrotic properties","volume":"250","author":"Beiert","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.mce.2019.01.013_bib8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.pharmthera.2010.04.005","article-title":"Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies","volume":"128","author":"Bernardo","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.mce.2019.01.013_bib9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1042\/CS20130105","article-title":"Relaxin improves multiple markers of wound healing and ameliorates the disturbed healing pattern of genetically diabetic mice","volume":"125","author":"Bitto","year":"2013","journal-title":"Clin. Sci."},{"key":"10.1016\/j.mce.2019.01.013_bib10","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.2337\/db13-0033","article-title":"Relaxin treatment reverses insulin resistance in mice fed a high-fat diet","volume":"62","author":"Bonner","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.mce.2019.01.013_bib11","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/eurheartj\/ehq426","article-title":"Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment","volume":"32","author":"Borlaug","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.mce.2019.01.013_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.regpep.2010.09.001","article-title":"Relaxin inhibits early steps in vascular inflammation","volume":"166","author":"Brecht","year":"2011","journal-title":"Regul. Pept."},{"key":"10.1016\/j.mce.2019.01.013_bib13","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1023\/A:1018901009062","article-title":"The pharmacokinetics of recombinant human relaxin in nonpregnant women after intravenous, intravaginal, and intracervical administration","volume":"10","author":"Chen","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.mce.2019.01.013_bib14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/ki.2013.518","article-title":"Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis","volume":"86","author":"Chow","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.mce.2019.01.013_bib15","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1096\/fj.01-0070com","article-title":"The pregnancy hormone relaxin is a player in human heart failure","volume":"15","author":"Dschietzig","year":"2001","journal-title":"FASEB J."},{"key":"10.1016\/j.mce.2019.01.013_bib16","doi-asserted-by":"crossref","DOI":"10.1006\/bbrc.2001.5946","article-title":"Flow-induced pressure differentially regulates endothelin-1, urotensin II, adrenomedullin, and relaxin in pulmonary vascular endothelium","volume":"289","author":"Dschietzig","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.mce.2019.01.013_bib17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.RES.0000051884.27117.7E","article-title":"Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptors via ERK-1\/2 kinases and nuclear factor-kappaB","volume":"92","author":"Dschietzig","year":"2003","journal-title":"Circ. Res."},{"key":"10.1016\/j.mce.2019.01.013_bib18","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1096\/fj.03-1120fje","article-title":"Identification of the pregnancy hormone relaxin as glucocorticoid receptor agonist","volume":"18","author":"Dschietzig","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.mce.2019.01.013_bib19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1196\/annals.1282.066","article-title":"Myocardial relaxin counteracts hypertrophy in hypertensive rats","volume":"1041","author":"Dschietzig","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.mce.2019.01.013_bib20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cardfail.2009.01.008","article-title":"Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial","volume":"15","author":"Dschietzig","year":"2009","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.mce.2019.01.013_bib21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/cvr\/cvs149","article-title":"Relaxin improves TNF-alpha-induced endothelial dysfunction: role of glucocorticoid receptor and phosphatidylinositol 3-kinase signalling","volume":"95","author":"Dschietzig","year":"2012","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.mce.2019.01.013_bib22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0008-6363(02)00663-6","article-title":"Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: a gender-specific phenotype","volume":"57","author":"Du","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.mce.2019.01.013_bib23","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1161\/01.CIR.98.16.1684","article-title":"Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction","volume":"98","author":"Dupuis","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.mce.2019.01.013_bib24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.114.009472","article-title":"International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides","volume":"67","author":"Halls","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.mce.2019.01.013_bib25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fphar.2016.00185","article-title":"Bioerodable PLGA-based microparticles for producing sustained-release drug formulations and strategies for improving drug loading","volume":"7","author":"Han","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.mce.2019.01.013_bib26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1523-1755.2005.00384.x","article-title":"The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway","volume":"68","author":"Heeg","year":"2005","journal-title":"Kidney Int."},{"key":"10.1016\/j.mce.2019.01.013_bib27","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.hrthm.2015.12.030","article-title":"Relaxin suppresses atrial fibrillation in aged rats by reversing fibrosis and upregulating Na+ channels","volume":"13","author":"Henry","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.mce.2019.01.013_bib28","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1095\/biolreprod.110.089201","article-title":"Relaxin modulates proinflammatory cytokine secretion from human decidual macrophages","volume":"85","author":"Horton","year":"2011","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.mce.2019.01.013_bib29","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/hep.29787","article-title":"Recombinant relaxin protects liver transplants from ischemia damage via hepatocyte glucocorticoid receptor: from bench-to-bedside","volume":"68","author":"Kageyama","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.mce.2019.01.013_bib30","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1210\/en.2004-0515","article-title":"Genetic targeting of relaxin and insulin-like factor 3 receptors in mice","volume":"145","author":"Kamat","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2019.01.013_bib31","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/art.24380","article-title":"Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement. A randomized, double-blind, placebo-controlled trial","volume":"60","author":"Khanna","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.mce.2019.01.013_bib32","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1128\/MCB.24.2.687-696.2004","article-title":"Impaired nipple development and parturition in LGR7 knockout mice","volume":"24","author":"Krajnc-Franken","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.mce.2019.01.013_bib33","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1161\/01.HYP.0000171930.00697.2f","article-title":"Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats","volume":"46","author":"Lekgabe","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.mce.2019.01.013_bib34","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.1210\/en.2006-0533","article-title":"The effects of relaxin and estrogen deficiency on collagen deposition and hypertrophy of nonreproductive organs","volume":"147","author":"Lekgabe","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2019.01.013_bib35","doi-asserted-by":"crossref","first-page":"e0190935","DOI":"10.1371\/journal.pone.0190935","article-title":"Relaxin reverses inflammatory and immune signals in aged hearts","volume":"13","author":"Martin","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.mce.2019.01.013_bib36","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.amjcard.2017.04.056","article-title":"How trialists and pharmaceutical sponsors have failed us by thinking that acute heart failure is a 48-hour illness","volume":"120","author":"McCullough","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.mce.2019.01.013_bib37","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1210\/en.2010-1126","article-title":"Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide","volume":"152","author":"McGuane","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2019.01.013_bib38","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1096\/fj.08-120857","article-title":"Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2","volume":"23","author":"Mookerjee","year":"2009","journal-title":"FASEB J."},{"key":"10.1016\/j.mce.2019.01.013_bib39","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1210\/en.2006-1324","article-title":"Relaxin antagonizes hypertrophy and apoptosis in neonatal rat cardiomyocytes","volume":"148","author":"Moore","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2019.01.013_bib41","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1056\/NEJMoa1601895","article-title":"Effect of ularitide on cardiovascular mortality in acute heart failure","volume":"376","author":"Packer","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mce.2019.01.013_bib42","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/CIRCRESAHA.113.301646","article-title":"Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts","volume":"113","author":"Parikh","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.mce.2019.01.013_bib43","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1093\/eurheartj\/ehm037","article-title":"How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology","volume":"28","author":"Paulus","year":"2007","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.mce.2019.01.013_bib44","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.mce.2019.01.013_bib45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1096\/fj.02-0449fje","article-title":"Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis","volume":"17","author":"Samuel","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.mce.2019.01.013_bib46","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1210\/en.2004-0209","article-title":"Relaxin modulates cardiac fibroblast proliferation, differentiation and collagen production and reverses cardiac fibrosis in vivo","volume":"145","author":"Samuel","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2019.01.013_bib47","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1210\/en.2008-0250","article-title":"Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy","volume":"149","author":"Samuel","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2019.01.013_bib48","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/HYPERTENSIONAHA.114.03594","article-title":"Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease","volume":"64","author":"Samuel","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.mce.2019.01.013_bib49","doi-asserted-by":"crossref","first-page":"F1355","DOI":"10.1152\/ajprenal.00407.2014","article-title":"Serelaxin reduces oxidative stress and asymmetric dimethylarginine in angiotensin II-induced hypertension","volume":"307","author":"Sasser","year":"2014","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"10.1016\/j.mce.2019.01.013_bib50","first-page":"302","article-title":"Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis","volume":"25","author":"Seibold","year":"1998","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.mce.2019.01.013_bib51","doi-asserted-by":"crossref","first-page":"871","DOI":"10.7326\/0003-4819-132-11-200006060-00004","article-title":"Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial","volume":"132","author":"Seibold","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.mce.2019.01.013_bib52","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fphar.2015.00286","article-title":"Advances and challenges of liposome assisted drug delivery","volume":"6","author":"Sercombe","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.mce.2019.01.013_bib53","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circ"},{"key":"10.1016\/j.mce.2019.01.013_bib54","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/01.CIR.102.10.1132","article-title":"Pulmonary release and coronary and peripheral consumption of big endothelin and endothelin-1 in severe heart failure: acute effects of vasodilator therapy","volume":"102","author":"Stangl","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.mce.2019.01.013_bib55","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(09)60622-X","article-title":"Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study","volume":"373","author":"Teerlink","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2019.01.013_bib56","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","article-title":"Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial","volume":"381","author":"Teerlink","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2019.01.013_bib57","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.mce.2019.01.013_bib58","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/eurjhf\/hfr060","article-title":"Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF","volume":"13","author":"Voors","year":"2011","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.mce.2019.01.013_bib59","first-page":"302","article-title":"Diastolic heart failure: progress, treatment challenges, and prevention","volume":"27","author":"Wood","year":"2011","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.mce.2019.01.013_bib60","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jacc.2005.09.022","article-title":"Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database","volume":"47","author":"Yancy","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.mce.2019.01.013_bib61","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1093\/eurheartj\/ehy626","article-title":"Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14\u2009964 patients in the European Society of Cardiology Heart Failure Long-Term Registry","volume":"39","author":"Zafrir","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.mce.2019.01.013_bib62","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1210\/endo.140.1.6404","article-title":"Mice without a functional relaxin gene are unable to deliver milk to their pups","volume":"140","author":"Zhao","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2019.01.013_bib63","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1161\/CIRCULATIONAHA.114.013215","article-title":"Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin","volume":"131","author":"Zile","year":"2015","journal-title":"Circulation"}],"container-title":["Molecular and Cellular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720719300139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720719300139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:08:11Z","timestamp":1759586891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303720719300139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":62,"alternative-id":["S0303720719300139"],"URL":"https:\/\/doi.org\/10.1016\/j.mce.2019.01.013","relation":{},"ISSN":["0303-7207"],"issn-type":[{"value":"0303-7207","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relaxin-2 for heart failure with preserved ejection fraction (HFpEF): Rationale for future clinical trials","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mce.2019.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}